Marwa Kaisey, MD
Neuromuscular Medicine · West Hollywood, CANPI 1790048734
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $174,211 of the $263,829 with a category attached, or 66.0%. 12 manufacturers reported payments, led by Genentech USA, Inc. at 44.4% of the total. 2025 is the largest year on record at $67,913, 4.7 times the $14,340 reported in 2019.
Across 224 payments — averaging $1177.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$117K
- Biogen$67K
- TG Therapeutics, Inc.$60K
- EMD Serono, Inc.$10K
- AstraZeneca$6K
- Novartis$2K
- plus $2K from 6 others
Across 5 payments — averaging $8289.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$41K
What the payments were for
- Consulting fees$67,52126%
- Speaking & faculty fees$174,21166%
- Travel & lodging$18,1807%
- Food & beverage$3,9161%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 103 | $117,253 |
| Biogen | 52 | $66,744 |
| TG Therapeutics, Inc. | 43 | $59,756 |
| EMD Serono, Inc. | 9 | $10,332 |
| AstraZeneca | 6 | $5,880 |
| Novartis | 2 | $2,190 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,435 |
| Life Molecular Imaging Ltd | 4 | $91 |
| Amgen | 1 | $45 |
| Genentech, Inc. | 1 | $43 |
| Teva Pharmaceuticals USA, Inc. | 1 | $39 |
| AbbVie | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OCREVUS$100,752
- BRIUMVI$59,374
- Vumerity$31,035
- Ocrevus Zunovo$20,809
- TYSABRI$17,688
- Evobrutinib$9,730
- TECFIDERA$6,163
- AVONEX$3,013
- PLEGRIDY$3,013
- Enspryng$2,295
- KESIMPTA$2,128
- SOLIRIS$1,680
- Non-Covered Product$1,515
How this compares
$263,829 in reported general payments places this provider in the 85th percentile of 44 neuromuscular medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Baclofen | 21 | $633 |
Paid to pharmacies, not to this prescriber.
Other neuromuscular medicine in West Hollywood
- Samir MacwanRancho Mirage$983K
- Ali HabibOrange$445K
- Tahseen MozaffarOrange$428K
- Jeffrey RosenfeldFresno$361K
- John DayStanford$294K
- Namita GoyalOrange$174K
- Ana Tesi RochaPalo Alto$154K
- Jay HanOrange$126K
- Steven CramerLos Angeles$112K
- Khalid AlrasheedOrange$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.